Methods and compositions for stimulating hair growth are disclosed. Compositions for stimulating hair growth include two or more of hyaluronic acid, osteopontin, and another CD44 binding ligand. Methods for stimulating hair growth include administering such composition into the skin of a patient.

It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G.sub.0/G.sub.1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G.sub.0/G.sub.1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.

Compositions and methods for treating and/or reducing risk of development or progression of neuroinflammation and neurodegeneration, comprising HSP60 e.g., for nasal administration, and IGFBPL1, e.g., for nasal, systemic, or ocular, e.g., intravitreal, administration.

A non-immunogenic two-part clotting composition derived from human umbilical cords and methods of making thereof. The non-immunogenic two-part clotting composition may be used for dental purposes (periodontic and/or endodontic purposes) such as packing a subject's gum post-tooth extraction and/or for other wound packing purposes.

A non-immunogenic two-part clotting composition derived from human umbilical cords and methods of making thereof. The non-immunogenic two-part clotting composition may be used for dental purposes (periodontic and/or endodontic purposes) such as packing a subject's gum post-tooth extraction and/or for other wound packing purposes.

It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G.sub.0/G.sub.1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G.sub.0/G.sub.1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.

Physiological saline solutions (PSS) and methods for making and using same are disclosed relating to extracorporeal fetal care. In one aspect, disclosed herein is a PSS comprising: an aqueous solvent; from about 1.0 mM to about 2.0 mM calcium chloride; from about 3.0 mM to about 5.0 mM potassium chloride; from about 15.0 mM to about 20 mM sodium bicarbonate; from about 90 mM to about 110 mM sodium chloride; and from about 9 to about 13 mM sodium acetate; and optionally at least one buffering agent wherein the solution has a pH ranging from about 7.0 to about 7.4. In this or other aspects the solution has an osmolarity ranging from about 250 to about 270 mOsm.

Physiological saline solutions (PSS) and methods for making and using same are disclosed relating to extracorporeal fetal care. In one aspect, disclosed herein is a PSS comprising: an aqueous solvent; from about 1.0 mM to about 2.0 mM calcium chloride; from about 3.0 mM to about 5.0 mM potassium chloride; from about 15.0 mM to about 20 mM sodium bicarbonate; from about 90 mM to about 110 mM sodium chloride; and from about 9 to about 13 mM sodium acetate; and optionally at least one buffering agent wherein the solution has a pH ranging from about 7.0 to about 7.4. In this or other aspects the solution has an osmolarity ranging from about 250 to about 270 mOsm.

The present invention provides stable, pure and potent compositions optimized for administration to neonates and/or preterm infants, and use of the same in methods for treating intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), and/or chronic lung disease of prematurity (CLD), comprising administering to a subject in need of treatment a pharmaceutical composition comprising insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), and a polysorbate 20 surfactant at high effective doses in low volumes in an infant resulting high serum IGF-1 exposure and treatment of IVH, BPD and/or CLD. In some aspects, provided herein are methods for manufacturing the compositions comprising a single-use bag, wherein the compositions have improved stability, reduced oxidation and increased potency. In some aspects, the methods provided result in reduced incidence of symptoms and features of intraventricular hemorrhage, bronchopulmonary dysplasia, right ventricular hypertrophy (RVH), pulmonary hypertension (PH), necrotizing enterocolitis, or chronic lung disease of prematurity.

Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing bifunctional fusion polymers or nanoparticles. These fusion polymers and nanoparticles contain two or more domains: (i) sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous lesions and (ii) domains that bind to pharmaceutical agents. The drug-binding functionality of these fusion polymers and nanoparticles is based on high-affinity, non-covalent interactions.